Abstract:Background and aim Several effective antiviral drugs are now available; however, the risk of liver-related complications is still present. Low-level viremia (LLV), defined as a hepatitis B virus (HBV) deoxyribonucleic acid (DNA) load lower than 2000 IU/mL, is one of the major factors responsible for these complications. It has been reported that 22.7–43.1% of patients with HBV experience LLV. Herein, we aimed to explore the risk factors for very LLV (VLLV) during antiviral treatment. Methods We collected data of patients with chronic hepatitis B (CHB) who received nucleos(t)ide analog treatment from October 2016 to April 2021. VLLV was defined as an HBV DNA load of 9–20 IU/mL. A total of 139 patients with LLV were matched with 139 patients with a sustained virological response at a 1:1 ratio according to age and gender. Results Seropositivity rates for hepatitis B e antigen (HBeAg) (45.3% vs. 17.3%, P < 0.001) and hepatitis B surface antigen (HBsAg, 3.11 ± 0.68 lg IU/mL vs. 2.54 ± 1.04 lg IU/mL, P < 0.001) and alanine aminotransferase levels (30.34 ± 15.08 U/L vs. 26.15 ± 16.66 U/L, P = 0.040) in the two groups were significantly different. The multivariate analysis showed that both HBeAg seropositivity (adjusted odd ratio (aOR), 3.63; 95% confidence interval (CI): 1.98–6.64; P < 0.001) and HBsAg levels (aOR, 2.21; 95% CI: 1.53–3.20; P < 0.001) are independent risk factors for VLLV. During the multivariate analysis in the subgroup of HBeAg-positive patients, male gender (aOR, 3.68; 95% CI: 1.23–10.76; P = 0.017) and high HBsAg (aOR, 4.86; 95% CI: 1.73–13.64; P = 0.003) levels were significantly correlated with VLLV. However, this was not the case in HBeAg-negative patients (P > 0.050). HBeAg seropositivity (aOR, 5.08; 95% CI: 2.15–12.02; P < 0.001 vs. aOR, 2.78; 95% CI: 1.16–7.00; P = 0.022) and HBsAg levels (aOR, 2.75; 95% CI: 1.41–5.37; P = 0.003 vs. aOR, 2.10; 95% CI: 1.27–3.46; P = 0.004) significantly increased the risk of VLLV, irrespective of the age group. Both HBsAg (area under the receiver operating characteristic curve (AUC), 0.681; 95% CI: 0.623–0.736; P < 0.001) and HBeAg (AUC, 0.640; 95% CI: 0.581–0.697; P < 0.001) had certain predictive value for VLLV. Conclusion HBeAg seropositivity and higher HBsAg levels were not only risk factors for VLLV but also predicted its occurrence. When a patient with CHB remains HBeAg seropositive with high HBsAg levels after antiviral treatment for 48 weeks, emphasis should be placed on the potential occurrence of VLLV, warranting the use of highly sensitive HBV DNA detection methods.

Elevated hepatitis B virus RNA levels in HBeAg‐positive patients with low‐level viraemia or previous low‐level viraemia

[Relationship between the quantitative results of HBV DNA and HBV markers (HBV M) in population with low-level HBsAg].

HBcrAgandpgRNAand the therapeutic effect inHBeAg-positive patients receiving anti-viral therapy, baseline serum HBV-RNAis a powerful predictor of response.

Analysis on Clinical Features and Immunity in Chronic Hepatitis B Virus Infected Patients with Low-Level Hbsag

High serum IL-21 levels after 12 weeks of antiviral therapy predict HBeAg seroconversion in chronic hepatitis B.

HBsAg Levels in HBeAg-positive Chronic Hepatitis B Patients with Different Immune Conditions.

Serum HBeAg and HBV DNA Levels Are Not Always Proportional and Only High Levels of HBeAg Most Likely Correlate with High Levels of HBV DNA: A Community-Based Study.

Elevated Hepatitis B virus RNA levels in hepatocellular carcinoma patients compared to cirrhotic individuals: A propensity score matched analysis

[Serum hepatitis B virus pregenomic RNA profiles in patients with chronic hepatitis B on long-term antiviral therapy]

Low-level viremia in nucleoside analog-treated chronic hepatitis B patients

Hepatitis B surface antigen levels during natural history of chronic hepatitis B: a Chinese perspective study.

Serum hepatitis B virus RNA is a predictor of HBeAg seroconversion and virological response with entecavir treatment in chronic hepatitis B patients

Risk factors for very low-level viremia in patients with chronic hepatitis B virus infection: A single-center retrospective study

Serum HBV RNA levels among untreated adults with chronic hepatitis B in distinct immune phases and liver histopathology statuses

Characterization of Serum HBV RNA in Patients with Untreated HBeAg-Positive and -Negative Chronic Hepatitis B Infection

HBV RNA Profiles in Patients With Chronic Hepatitis B Under Different Disease Phases and Antiviral Therapy

Hepatitis B virus DNA levels and overall survival in hepatitis B‐related hepatocellular carcinoma patients with low‐level viremia

Relationship Between Hepatitis B Virus Dna Levels and Liver Histology in Patients with Chronic Hepatitis B

Prevalence and Associated Factors of Low-Level Viremia in Chronic Hepatitis B Patients After Long-Term Therapy with Nucleos(t)ide Analogs

Risk factors of low‐level viremia in chronic hepatitis B patients receiving Entecavir monotherapy: a retrospective cohort study

Risk factors related to low-level viraemia in chronic hepatitis B patients receiving entecavir treatment